Evaluation of a community-based HIV test and start program in a conflict affected rural area of Yambio County, South Sudan.
Adult
Anti-HIV Agents
/ therapeutic use
Armed Conflicts
CD4 Lymphocyte Count
Counseling
Female
Follow-Up Studies
HIV Infections
/ diagnosis
HIV Testing
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Patient Acceptance of Health Care
Residence Characteristics
Rural Population
South Sudan
Treatment Outcome
Viral Load
/ immunology
Young Adult
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
05
03
2020
accepted:
24
06
2021
entrez:
12
7
2021
pubmed:
13
7
2021
medline:
17
11
2021
Statut:
epublish
Résumé
Antiretroviral therapy (ART) coverage in South Sudan is around 10%. Access to HIV care in settings with low ART coverage or conflict affected is still low; innovative strategies are needed to increase access and ensure continuation of ART during instability. A pilot HIV test and start project was implemented in a conflict-affected area of South Sudan. In a retrospective analysis, we determined the feasibility and outcomes of this intervention. Programme data from July 2015 to June 2018 was analysed. The project involved five mobile teams offering HIV counselling and testing (HCT) and same day ART initiation at community level. Baseline and follow-up information on clinical, immunological and viral load (VL) was routinely recorded, as well as treatment outcomes. A semi-qualitative study was conducted to assess acceptability of the program among beneficiaries and community members. By June 2018, 14824 people received counselling and testing for HIV and 498 (3.4%) tested positive. Out of those 395 (79.3%) started ART. A total of 72 ART patients were organized in 26 Community ART Groups (CAGs) and contingency plan was activated 9 times for 101 patients. Kaplan-Meier estimated retention in care (RIC) at 12 and 18 months was 80.6% [95% CI: 75.9-84.5%] and 69.9% [95% CI: 64.4-74.8%] respectively. RIC was significantly higher at 18 months in patients under community ART groups (CAGs) (90.9% versus 63.4% p<0.001) when compared to patients on regular follow up. VL suppression at 12 months was 90.3% and overall virological suppression reached 91.2%. A total of 279 persons were interviewed about the MSF program perception and acceptance: 98% had heard about the programme and 84% found it beneficial for the community, 98% accepted to be tested and only 4% found disadvantages to the programme. Our study shows that HCT and early ART initiation in conflict affected populations can be provided with good program outcomes. RIC and virological suppression are comparable with facility-based HIV programs and to those in stable contexts. This model could be extrapolated to other similar contexts with low access to ART and where security situation is a concern.
Sections du résumé
BACKGROUND
Antiretroviral therapy (ART) coverage in South Sudan is around 10%. Access to HIV care in settings with low ART coverage or conflict affected is still low; innovative strategies are needed to increase access and ensure continuation of ART during instability. A pilot HIV test and start project was implemented in a conflict-affected area of South Sudan. In a retrospective analysis, we determined the feasibility and outcomes of this intervention.
METHODS
Programme data from July 2015 to June 2018 was analysed. The project involved five mobile teams offering HIV counselling and testing (HCT) and same day ART initiation at community level. Baseline and follow-up information on clinical, immunological and viral load (VL) was routinely recorded, as well as treatment outcomes. A semi-qualitative study was conducted to assess acceptability of the program among beneficiaries and community members.
RESULTS
By June 2018, 14824 people received counselling and testing for HIV and 498 (3.4%) tested positive. Out of those 395 (79.3%) started ART. A total of 72 ART patients were organized in 26 Community ART Groups (CAGs) and contingency plan was activated 9 times for 101 patients. Kaplan-Meier estimated retention in care (RIC) at 12 and 18 months was 80.6% [95% CI: 75.9-84.5%] and 69.9% [95% CI: 64.4-74.8%] respectively. RIC was significantly higher at 18 months in patients under community ART groups (CAGs) (90.9% versus 63.4% p<0.001) when compared to patients on regular follow up. VL suppression at 12 months was 90.3% and overall virological suppression reached 91.2%. A total of 279 persons were interviewed about the MSF program perception and acceptance: 98% had heard about the programme and 84% found it beneficial for the community, 98% accepted to be tested and only 4% found disadvantages to the programme.
CONCLUSIONS
Our study shows that HCT and early ART initiation in conflict affected populations can be provided with good program outcomes. RIC and virological suppression are comparable with facility-based HIV programs and to those in stable contexts. This model could be extrapolated to other similar contexts with low access to ART and where security situation is a concern.
Identifiants
pubmed: 34252129
doi: 10.1371/journal.pone.0254331
pii: PONE-D-20-06492
pmc: PMC8274874
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Evaluation Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0254331Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
PLoS One. 2016 Oct 5;11(10):e0163365
pubmed: 27706174
AIDS. 2012 Jun 1;26(9):1131-9
pubmed: 22382143
Curr HIV/AIDS Rep. 2016 Oct;13(5):241-55
pubmed: 27475643
PLoS One. 2018 Jul 27;13(7):e0200737
pubmed: 30052637
J Acquir Immune Defic Syndr. 2012 Feb 1;59(2):e9-16
pubmed: 22067665
Clin Infect Dis. 2010 Mar 1;50(5):752-61
pubmed: 20121413
PLoS Med. 2013 Aug;10(8):e1001496
pubmed: 23966838
Trials. 2017 Aug 18;18(1):383
pubmed: 28821264
Clin Infect Dis. 2007 Jun 1;44(11):1493-9
pubmed: 17479948
J Int AIDS Soc. 2017 Jul 21;20(Suppl 4):21654
pubmed: 28770590
J Int AIDS Soc. 2017 Mar 28;20(1):21374
pubmed: 28406273
Soc Sci Med. 2013 Jun;86:9-16
pubmed: 23608089
PLoS Med. 2007 May;4(5):e129
pubmed: 17535100
Nature. 2015 Dec 3;528(7580):S77-85
pubmed: 26633769
Confl Health. 2010 Jun 17;4:12
pubmed: 20553624
PLoS Med. 2015 Sep 08;12(9):e1001873
pubmed: 26348035
AIDS Behav. 2018 Mar;22(3):1018-1024
pubmed: 28224322
Trop Med Int Health. 2017 Apr;22(4):375-387
pubmed: 28102610
Confl Health. 2018 Jul 2;12:30
pubmed: 29988565
AIDS. 2008 Aug;22 Suppl 2:S95-103
pubmed: 18641476
Med Confl Surviv. 2013 Jul-Sep;29(3):198-215
pubmed: 24133930
BMC Public Health. 2011 Sep 26;11:730
pubmed: 21943164
BMJ Open. 2017 Aug 11;7(8):e016800
pubmed: 28801427
Glob Public Health. 2011;6(1):83-97
pubmed: 20509066
J Acquir Immune Defic Syndr. 2013 Sep 1;64(1):e1-8
pubmed: 23714740
Trials. 2013 Jul 23;14:230
pubmed: 23880306